| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c782c7a5d04a277fa0d097493449e3cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_446116d46200de9e5929b44025b4b168
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_34646176f17aceaa8bf976cfc39e77ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b861807585085645a0c9b91f3a789106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d412d4c97eed870462d0a9e966f72640 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5047 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5078 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50 |
| filingDate |
2003-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e82f33900a4ccbb1dec6c05e10d3f19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7298c4a5c4d1a4977104fd445effed8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc88ecfcb2621103ea983484dec9558b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_606c6e79d957344771918be480aa4d5c |
| publicationDate |
2004-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2004047718-A2 |
| titleOfInvention |
Process for manufacturing sustained release microbeads containing venlafaxine hci |
| abstract |
The present invention relates to viable continuous process for manufacture of agglomeration free, high yield (generally atleast about 95% w/w), uniformly shaped and sized, stable novel pharmaceutical composition of adequate strength comprising upto about 70%w/w of Venlafaxine or its pharmaceutical acceptable salt which is free of organic acid for once a day dosing. Sustained release composition comprising of Venlafaxine HCI provides pH independent release of Venlafaxine HCI atleast for a period of 10 hours without any latent period and can be encapsulated in smallest capsule size 5 for therapeutic effective of Venlafaxine thus providing patient easy to consume dosage form. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007039569-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7897179-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102935071-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006010605-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006010605-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102935071-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8062666-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-009957-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8557282-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105055330-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105055330-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8906419-B2 |
| priorityDate |
2002-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |